These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34193869)

  • 1. CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.
    Hoffmann D; Corleis B; Rauch S; Roth N; Mühe J; Halwe NJ; Ulrich L; Fricke C; Schön J; Kraft A; Breithaupt A; Wernike K; Michelitsch A; Sick F; Wylezich C; Hoffmann B; Thran M; Thess A; Mueller SO; Mettenleiter TC; Petsch B; Dorhoi A; Beer M
    Nat Commun; 2021 Jun; 12(1):4048. PubMed ID: 34193869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; López-Bravo M; Zamora C; Sin L; Álvarez E; Sorzano CÓS; Sánchez-Cordón PJ; Casasnovas JM; Astorgano D; García-Arriaza J; Anthiya S; Borrajo ML; Lou G; Cuesta B; Franceschini L; Gelpí JL; Thielemans K; Sisteré-Oró M; Meyerhans A; García F; Esteban I; López-Bigas N; Plana M; Alonso MJ; Esteban M; Gómez CE
    Emerg Microbes Infect; 2024 Dec; 13(1):2387906. PubMed ID: 39087555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
    Radvak P; Kwon HJ; Kosikova M; Ortega-Rodriguez U; Xiang R; Phue JN; Shen RF; Rozzelle J; Kapoor N; Rabara T; Fairman J; Xie H
    Nat Commun; 2021 Nov; 12(1):6559. PubMed ID: 34772941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.
    Wong TY; Horspool AM; Russ BP; Ye C; Lee KS; Winters MT; Bevere JR; Miller OA; Rader NA; Cooper M; Kieffer T; Sourimant J; Greninger AL; Plemper RK; Denvir J; Cyphert HA; Barbier M; Torrelles JB; Martinez I; Martinez-Sobrido L; Damron FH
    J Virol; 2022 Mar; 96(6):e0218421. PubMed ID: 35080423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 14. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
    Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
    Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.
    Silvas JA; Vasquez DM; Park JG; Chiem K; Allué-Guardia A; Garcia-Vilanova A; Platt RN; Miorin L; Kehrer T; Cupic A; Gonzalez-Reiche AS; Bakel HV; García-Sastre A; Anderson T; Torrelles JB; Ye C; Martinez-Sobrido L
    J Virol; 2021 Aug; 95(17):e0040221. PubMed ID: 34133899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.
    Fan S; Xiao K; Li D; Zhao H; Zhang J; Yu L; Chang P; Zhu S; Xu X; Liao Y; Ji T; Jiang G; Yan D; Zeng F; Duan S; Xia B; Wang L; Yang F; He Z; Song Y; Cui P; Li X; Zhang Y; Zheng B; Zhang Y; Xu W; Li Q
    Emerg Microbes Infect; 2022 Dec; 11(1):212-226. PubMed ID: 34931939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
    Gebre MS; Rauch S; Roth N; Yu J; Chandrashekar A; Mercado NB; He X; Liu J; McMahan K; Martinot A; Martinez DR; Giffin V; Hope D; Patel S; Sellers D; Sanborn O; Barrett J; Liu X; Cole AC; Pessaint L; Valentin D; Flinchbaugh Z; Yalley-Ogunro J; Muench J; Brown R; Cook A; Teow E; Andersen H; Lewis MG; Boon ACM; Baric RS; Mueller SO; Petsch B; Barouch DH
    Nature; 2022 Jan; 601(7893):410-414. PubMed ID: 34794169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.